/

ONCO

Onconetix, Inc.Pre-market

0.5550−0.04 −6.00%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayPre-market 0.5402 −2.67%

Open

0.5520

Prev close

0.5904

Day range

0.53500.5786

52-week range

0.5350200.00

Volume

325.21K0.11×

Mkt cap

2.91M

P/E ttm

0.00

Fwd P/E

-0.65

EPS ttm

310.39

Div yield

0.00%

Earnings

—

From 52w high

−99.72%

Price Chart

Yahoo Finance · delayed

ONCOOct 13, 2026O 0.5520H 0.5800L 0.5350C 0.5550−0.0350 (−5.93%)Vol 325.20K

SMA 500.7538
SMA 20019.0618

1Y change −99.70% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ONCO Onconetix, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −16.04%
1 month: −26.59%
3 months: −34.63%
6 months: −93.90%
Year to date: −99.29%
1 year: −99.70%

Valuation & ownership

Market cap: 2.91M
Enterprise value: −3.56M
P/E (ttm): 0.00
Forward P/E: -0.65
PEG ratio: —
Price / book: 0.16
Price / sales (ttm): 4.50
EV / EBITDA: 0.46
EPS (ttm): 310.39
EPS (forward): -0.8500
Beta (5y monthly): 2.61
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 5.24M
Float: 3.95M
Short % of float: 9.34%
Short ratio (days): 0.09
Held by insiders: 0.13%
Held by institutions: 5.52%
Avg volume (3m): 2.96M
50-day average: 0.7589
200-day average: 19.44
52-week change: −99.70%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 38.6
vs 50-day SMA: −26.37%
vs 200-day SMA: −97.09%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 22.77%
Realised vol (20d, ann.): 177.9%
From 52-week high: −99.72%
From 52-week low: +3.74%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 645.82K
Revenue growth (yoy): −83.90%
Earnings growth (yoy): —
Gross margin: 80.40%
Operating margin: -13112.09%
Profit margin: 0.00%

DES

About Onconetix, Inc.

Yahoo Finance profile

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Sector: Healthcare
Industry: Biotechnology
Employees: 2
Headquarters: Cincinnati, OH, United States
Website: onconetix.com
Officers: Ms. Karina M. Fedasz Interim Chief Financial Officer
Mr. David Allan White C.A., C.P.A., ICD.D Chief Executive Officer
Mr. Andrew D. Skibo Ph.D. Global Head of Biologics Operations
Mr. Theodore Scott Yoho Head of Business Development

SEAS

Seasonality · ONCO

2022–2026 · monthly returns

Strongest month May +20.25%Weakest month Nov −32.54%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-9.0	-52.9	-55.5	-53.4	-82.7	-5.8	-26.8	-24.2	24.7	-29.0			−99.3%
2025	-13.7	-54.6	-68.4	-6.4	6.8	-28.1	-25.4	-17.7	6.1	9.0	-18.0	-43.9	−97.1%
2024	-3.5	-10.5	-9.9	-24.0	76.1	-18.9	-7.2	-12.3	-4.4	-44.4	-76.1	-8.7	−92.0%
2023	11.8	-4.9	-8.5	0.0	-24.8	40.4	0.0	-29.3	-35.9	-23.8	-38.5	-17.5	−82.0%
2022			13.9	-93.6	22.8	-51.7	57.3	-6.0	-45.7	-27.5	2.4	-13.4	−97.8%

INSD

Insider Activity · ONCO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

5.56M shares

Sells, 6 months

782.2K shares

Net shares

+4.78M

Net change in insider shares

−100.10%

Date	Insider	Transaction	Shares	Value
Apr 20, 2026	Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security	Sale at price 0.69 per share.	49.7K	$34.30K
Apr 19, 2026	Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security	Sale at price 0.73 - 0.75 per share.	148.3K	$110.17K
Apr 16, 2026	Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.73 per share.	34.6K	$25.28K
Apr 14, 2026	Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.76 - 0.77 per share.	166.9K	$127.59K
Aug 14, 2025	Tarsh SimonDirector	Stock Award(Grant) at price 0.00 per share.	618	—
Aug 14, 2025	Ramdeen Timothy R.Director	Stock Award(Grant) at price 0.00 per share.	618	—
Aug 14, 2025	Meier Thomas Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	618	—
Aug 14, 2025	Oakley Andrew J.Director	Stock Award(Grant) at price 0.00 per share.	618	—
Mar 20, 2025	Oakley Andrew J.Director	Stock Award(Grant) at price 0.00 per share.	1.7K	—
Dec 19, 2024	Bruhlmann ChristianOfficer	Stock Award(Grant) at price 0.00 per share.	177.5K	—
Dec 19, 2024	Schiess RalphChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	177.5K	—

ONCO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ONCO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Onconetix, Inc.

Seasonality · ONCO

Insider Activity · ONCO

Congress Trades · ONCO

Investors Holding ONCO

Investors Holding ONCO

Congress Trades · ONCO

Insider Activity · ONCO

Seasonality · ONCO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Onconetix, Inc.

Earnings & Dividends

News